Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV, Randomized, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicenter Clinical Study to Evaluate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
X
Search
Trial Profile

A Phase IV, Randomized, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicenter Clinical Study to Evaluate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Samsung Bioepis

    • Most Recent Events

    • 12 Mar 2024 Results assessing the pharmacokinetics (PK), efficacy, safety, and immunogenicity in patients with moderate to severe plaque psoriasis who switched between RP adalimumab and the high concentration formulation SB5 (40 mg/0.4 mL) adalimumab biosimilar to those receiving RP continuously, presented at the American Academy of Dermatology annual Meeting 2024.
    • 09 Mar 2024 Primary endpoint (Maximum serum concentration during the dosing interval (Cmax)) (week 23-25), has been met according to a Samsung Bioepis media release.
    • 09 Mar 2024 Primary endpoint (Area under the concentration-time curve over the dosing interval (AUCtau)) (week 23-25), has been met according to a Samsung Bioepis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top